Antithrombotic therapy in peripheral arterial occlusive disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Chest

Volumn 126, Issue 3 SUPPL., 2004, Pages 609S-626S

  Clagett, G Patrick ^a   Sobel, Michael ^b   Jackson, Mark R ^b   Lip, Gregory Y H ^b   Tangelder, Marco ^b   Verhaeghe, Raymond ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE

Author keywords

Anticoagulants; Antithrombotic; Occlusive artery disease; Peripheral artery

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BERAPROST; CARNITINE; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; FISH OIL; HEPARIN; KETANSERIN; LOW MOLECULAR WEIGHT HEPARIN; NAFTIDROFURYL; NIFEDIPINE; PENTOXIFYLLINE; PICOTAMIDE; PROSTACYCLIN; PROSTAGLANDIN E1; PROTAMINE; PROUROKINASE; RETEPLASE; STREPTOKINASE; SULFINPYRAZONE; SULOCTIDIL; TICLOPIDINE; UNINDEXED DRUG; UROKINASE; WARFARIN;

ANTICOAGULANT THERAPY; ARTERY EMBOLISM; ARTERY THROMBOSIS; BLEEDING; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CATHETERIZATION; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CLIP; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; CONSERVATIVE TREATMENT; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; EVIDENCE BASED MEDICINE; FEMOROPOPLITEAL BYPASS; FIBRINOLYTIC THERAPY; HUMAN; INGUINAL REGION; INTERMITTENT CLAUDICATION; LEUKOPENIA; LIMB ISCHEMIA; META ANALYSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VASCULAR SURGERY; VEIN BYPASS;

EID: 4644319949     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.3_suppl.609S     Document Type: Conference Paper

References (154)

1. Reunanen A, Takkunen H, Aromaa A. Prevalence of intermittent claudication and its effect on mortality. Acta Med Scand 1982; 211:249-256
2. Jelnes R, Gaardsting O, Hougaard Jensen K, et al. Fate in intermittent claudication: outcome and risk factors. BMJ 1986; 293:1137-1140
3. Skau T, Jonsson B. Prevalence of symptomatic leg ischaemia in a Swedish community: an epidemiological study. Eur J Vasc Surg 1993; 7:432-437
4. Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation 1985; 71:510-515
5. Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the cardiovascular health study. Circulation 1993; 88:837-845
6. Cox GS, Hertzer NR, Young JR, et al. Nonoperative treatment of superficial femoral artery disease: long-term follow-up. J Vasc Surg 1993; 17:172-182
7. Cronenwett JL, Warner KG, Zelenock GB, et al. Intermittent claudication. Arch Surg 1984; 119:430-436
8. Howell MA, Colgan MP, Seeger RW, et al. Relationship of severity of lower limb peripheral vascular disease to mortality and morbidity: a six-year follow-up study. J Vasc Surg 1989; 9:691-697
9. Ogren M, Hedblad B, Isacsson SO, et al. Non-invasivelv detected carotid stenosis and ischaemic heart disease in men with leg arteriosclerosis. Lancet 1993; 342:1138-1141
10. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev (database online). Issue 2, 2000
11. Regensteiner JG, Hiatt WR. Current medical therapies for patients with peripheral arterial disease: a critical review. Am J Med 2002; 112:49-57
12. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344:1608-1621
13. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86
14. Hess H, Mietaschik A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease: a prospective double-blind arteriographically controlled trial. Lancet 1985; 1:416-419
15. Libretti A, Catalano M. Treatment of claudication with dipyridamole and aspirin. Int J Clin Pharmacol Res 1986; 6:59-60
16. Giansante C, Calabrese S, Fisicaro M, et al. Treatment of intermittent claudication with antiplatelet agents. J Int Med Res 1990; 18:400-407
17. Goldhaber SZ, Manson JE, Stampfer MJ, et al. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study. Lancet 1992; 340:143-145
18. Boissel JP, Peyrieux JC, Destors JM. Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs? Thromb Haemost 1989; 62:681-685
19. Arcan JC, Panak E. Ticlopidine in the treatment of peripheral occlusive arterial disease. Semin Thromb Haemost 1989; 15:167-170
20. Balsano F, Coccheri S, Libretti A, et al. Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. J Lab Clin Med 1989; 114:84-91
21. Bergqvist D, Almgren B, Dickinson JP. Reduction of the requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: results From the Swedish Ticlopidine Multicentre Study (STIMS). Eur J Vasc Endovasc Surg 1995; 10:69-76
22. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348:1329-1339
23. Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998; 27:267-275
24. Dawson DL, Cutler BS, Meissner MH, et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98:678-686
25. Dawson DL, DeMaioribus CA, Hagino RT, et al. The effect of withdrawal of drugs treating intermittent claudication. Am J Surg 1999; 178:141-146
26. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacologic treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999; 159:2041-2050
27. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000; 109:523-530
28. Angelkort B, Maurin N, Bouteng K. Influence of pentoxifylline on erythrocyte deformability in peripheral occlusive arterial disease. Curr Med Res Opin 1979; 6:255-258
29. Johnson WC, Sentissi JM, Baldwin D, et al. Treatment of claudication with pentoxifylline: are benefits related to improvement in viscosity? J Vasc Surg 1987; 6:211-216
30. Angelkort B, Kiesewetter H. Influence of risk factors and coagulation phenomena on the fluidity of blood in chronic-arterial occlusive disease. Scand J Clin Lab Invest 1981; 156(suppl):185-188
31. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. Can Med Assoc J 1996; 155:1053-1059
32. Bollinger A, Frei C. Double blind study of pentoxifylline against placebo in patients with intermittent claudication. Pharmatherapeutica 1977; 1:557-562
33. DiPerri T, Guerrini M. Placebo controlled double blind study with pentoxifylline of walking performance in patients with intermittent claudication. Angiology 1983; 34:40-45
34. Roekaerts F, Deleers L. Trental 400 in the treatment of intermittent claudication: results of long-term, placebo-controlled administration. Angiology 1984; 35:396-406
35. Strano A, Davi G, Avellone G, et al. Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs. Angiology 1984; 35:459-466
36. Lindgarde F, Jelnes R, Bjorkman H, et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Circulation 1989: 80:1549-1556
37. Ciocon JO, Galindo-Ciocon D, Galindo DJ. A comparison between aspirin and pentoxifylline in relieving claudication due to peripheral vascular disease in the elderly. Angiology 1997; 48:237-240
38. Porter JM, Cutler BS, Lee BY, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982; 104:66-72
39. Dettori AG, Pini M, Moratti A, et al. Acenocoumarol and pentoxifylline in intermittent claudication: a controlled clinical study: the APIC study group. Angiology 1989; 40:237-248
40. Callus AS, Morley AA, Gleadow F, et al. Intermittent claudication: a double-blind crossover trial of pentoxifylline. Aust N Z J Med 1985; 15:402-409
41. Perhoniemi V, Salmenkivi K, Sundberg S, et al. Effects of flunarizine and pentoxifylline on walking distance and blood rheology in claudication. Angiology 1984; 35:366-372
42. Reilly DT, Quinton DN, Barrie WW. A controlled trial of pentoxifylline (Trental 400) in intermittent claudication: clinical, haemostatic and rheological effects. N Z Med J 1987; 100:445-447
43. Tonak J, Knecht H, Groitl H. Treatment of circulatory disturbances with pentoxifylline: a double blind study with Trental. Pharmatherapeutica 1983; 3(suppl 1):126-135
44. Radack K, Wyderski RJ. Conservative management of intermittent claudication. Ann Intern Med 1990; 113:135-146
45. Anand S, Creager M. Peripheral artery disease. Clin Evid 2002; June:79-90
46. Hiatt WR, Regensteiner JG, Hargarten ME, et al. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation 1990; 81:602-609
47. 1 prodrug, in patients with intermittent claudication. Circulation 1997; 95:2298-2302
48. 1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease: results of a prospective randomized, double-blind, multicenter clinical trial. J Vasc Surg 1984; 1:160-170
49. Scheffler P, de la Hamette D, Gross J, et al. Intensive vascular training in stage IIb of peripheral arterial occlusive disease; the additive effects of intravenous prostaglandin E, or intravenous pentoxifylline during training. Circulation 1994; 90:818-822
50. 1. Ann Intern Med 1999; 130:412-421
51. Belch JJF, Bell PRF, Creissen D, et al. Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Circulation 1997; 95:2298-2302
52. Cronenwett JL, Zelenock GB, Whitehouse WM, et al. Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructible peripheral arterial occlusive disease. Surgery 1986; 100:369-382
53. Nizankowski R, Krolikowski W, Bielatowicz J, et al. Prostacyclin for ischemic ulcers in peripheral arterial disease: a random assignment, placebo controlled study. Thromb Res 1985; 37:21-28
54. Belch JJF, McKay A, McArdle B, et al. Epoprostenol (prostacyclin) and severe arterial disease: a double-blind study. Lancet 1983; 1:315-317
55. Lievre M, Morand S, Besse B, et al. Oral beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Circulation 2000; 102:426-431
56. PACK Claudication Substudy Investigators. Randomized placebo-controlled, double-blind trial of ketanserin in claudicants: changes in claudication distance and ankle systolic pressure. Circulation 1989; 80:1544-1548
57. Verhaeghe R, Van Hoof A, Beyens GH. Controlled trial of suloctidil in intermittent claudication. J Cardiovasc Pharmacol 1981; 3:279-286
58. Gans ROB, Bilo HJG, Weersink EGL, et al. Fish oil supplementation in patients with stable claudication. Am J Surg 1990; 160:490-495
59. Clyne AC, Galland RB, Fox MJ, et al. A controlled trial of naftidrofuryl (Praxilene) in the treatment of intermittent claudication. Br J Surg 1980; 67:347-348
60. Greenhalgh RM. Naftidrofuryl for ischaemic rest pain: a controlled trial. Br J Surg 1981; 68:265-266
61. Balsano F, Violi F. Effect of picotamide on the clinical progression of peripheral vascular disease: a double-blind placebo-controlled study. Circulation 1993; 87:1563-1569
62. Cocozza M, Picano T, Olivero U, et al. Effects of picotamide, an antithromboxane agent, on carotid atherosclerotic evolution: a two-year, double-blind, placebo-controlled study in diabetic patients. Stroke 1995; 26:597-601
63. Girolami B, Bemardi E, Prins MH, et al. Antithrombotic drugs in the primary medical management of intermittent claudication: a meta-analysis. Thromb Haemost 1999; 81:715
64. Ernst E, Kollar L, Matrai, A. Hemodilution in peripheral arterial occlusive disease: placebo controlled randomized double-blind study with hydroxyethyl starch or dextran. Acta Med Austriaca 1991; 18(suppl):27-29
65. Kiesewetter H, Blume J, Jung F, et al. Haemodilution with medium molecular weight hydroxyethyl starch in patients with peripheral arterial occlusive disease stage lib. J Intern Med 1990; 227:107-114
66. Cosmi B, Conti E, Coccheri S. Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Cochrane Database Syst Rev (database online). Issue 2, 2002
67. Elliott JP Jr, Hageman JH, Szilagyi E, et al. Arterial embolization: problems of source, multiplicity, recurrence, and delayed treatments. Surgery 1980; 88:833-845
68. Abbott WM, Maloney RD, McCabe CC, et al. Arterial embolism: a 44-year perspective. Am J Surg 1982; 143:460-464
69. Kasirajan K, Haskal ZJ, Ouriel K. The use of mechanical thrombectomy devices in the management of acute peripheral arterial occlusive disease. J Vasc Interv Radiol 2001; 12:405-411
70. Morgan R, Belli AM. Percutaneous thrombectomy. Eur Radiol 2002; 12:205-217
71. Working Party on Thrombolysis in the Management of Limb Ischemia. Thrombolysis in the management of limb peripheral arterial occlusion: a consensus document. Am J Cardiol 1998; 81:207-218
72. Davidian MM, Powell A, Benenati J, et al. Initial results of reteplase in the treatment of acute lower extremity arterial occlusions. J Vasc Interv Radiol 2000; 11:289-294
73. Ouriel K, Katzen B, Mewissen M, et al. Reteplase in the treatment of peripheral arterial and venous occlusions: a pilot study. J Vasc Interv Radiol 2000; 11:849-854
74. Duda SH, Tepe G, Luz O, et al. Peripheral artery occlusion: treatment with abciximab plus urokinase versus urokinase alone: a randomized pilot trial (the PROMPT study). Radiology 2001; 221:689-696
75. Berridge DC, Gregson RHS, Hopkinson BR, et al. Randomized trial of intra-arterial recombinant tissue plasminogen activator, intravenous recombinant tissue plasminogen activator and intra-arterial streptokinase in peripheral arterial thrombolysis. Br J Surg 1991; 78:988-995
76. Meyerovitz MF, Goldhaber SZ, Reagan K, et al. Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial. Radiology 1990; 175:75-78
77. The STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity: the STILE trial. Ann Surg 1994; 220:251-268
78. Schweizer J, Altmann E, Florek HJ, et al. Comparison of tissue plasminogen activator and urokinase in the local infiltration thrombolysis of peripheral arterial occlusions. Eur J Radiol 1996; 23:64-73
79. Ouriel K, Kendarpa K, Schuerr DM, et al. Prourokinase versus urokinase for recanalization of peripheral occlusions, safety and efficacy: the PURPOSE trial. J Vasc Interv Radiol 1999; 10:1083-1091
80. Nilsson L, Albrechtsson U, Jonung T, et al. Surgical treatment versus thrombolysis in acute arterial occlusion: a randomized controlled study. Eur J Vasc Surg 1992; 6:189-193
81. Ouriel K, Shortell CK, De Weese JA, et al. A comparison of thrombolytic therapy with operative vascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg 1994; 19:1021-1030
82. Weaver FA, Comerota AJ, Youngblood M, et al. Surgical revascularization versus thrombolysis for nonembolic lower extremity native artery occlusions: results of a prospective randomized trial. J Vasc Surg 1996; 24:513-521
83. Comerota AJ, Weaver FA, Hosking JD, et al. Results of prospective, randomized trial of surgery versus thrombolysis for occluded lower extremity bypass grafts. Am J Surg 1996; 172:105-112
84. Ouriel K, Veith FJ, Sasahara AA. Thrombolysis or peripheral arterial surgery: phase I results. J Vasc Surg 1996; 23:64-75
85. Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med 1998; 338:1105-1111
86. Palfrayman SJ, Booth A, Michaels JA. A systematic review of intra-arterial thrombolytic therapy for lower-limb ischaemia. Eur J Vasc Endovasc Surg 2000; 19:143-157
87. Berridge DC, Kessel D, Robertson I. Surgery versus thrombolysis for acute limb ischaemia: initial management. Cochrane Database Syst Rev (database online). Issue 3, 2002
88. Galland RB, Magee TR, Whitman B, et al. Patency following successful thrombolysis of occluded vascular grafts. Eur J Vasc Endovasc Surg 2001; 22:157-160
89. Veith FJ, Gupta SK, Ascer E, et al. Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. J Vasc Surg 1986; 3:104-113
90. Taylor LM Jr, Edwards JM, Porter JM. Present status of reversed vein bypass grafting: five-year results of a modern series. J Vasc Surg 1990; 11:193-206
91. Wengerter KR, Veith FJ, Gupta SK, et al. Prospective randomized multicenter comparison of in situ and reversed vein infrapopliteal bypasses. J Vasc Surg 1991; 13:189-199
92. Eickhoff JH, Hansen HJB, Bromme A, et al. A randomized clinical trial of PTFE versus human umbilical vein for femoropopliteal bypass surgery: preliminary results. Br J Surg 1983; 70:85-88
93. McCollum C, Kenchington G, Alexander C, et al. PTFE or HUV for femoro-popliteal bypass: a multi-centre trial. Eur J Vasc Surg 1991; 5:435-443
94. Aalders GJ, van Vroonhoven TJMV. Polytetrafluoroethylene versus human umbilical vein in above-knee femoropopliteal bypass: six-year results of a randomized clinical trial. J Vasc Surg 1992; 16:816-824
95. Davies MG, Hagen PO. Pathophysiology of vein graft failure: a review. Eur J Vasc Endovasc Surg 1995; 9:7-18
96. Szilagy DE, Elliott JP, Hageman JH, et al. Biologic fate of autogenous vein implants as arterial substitutes: clinical, angiographic and histopathologic observations in femoro-popliteal operations for atherosclerosis. Ann Surg 1973; 178:232-246
97. Goldman MD, Simpson D, Hawker RJ, et al. Aspirin and dipyridamole reduced platelet deposition on prosthetic femoropopliteal grafts in man. Ann Surg 1983; 198:713-716
98. Pumphrey CW, Chesebro JH, Dewanjee MK, et al. In vivo quantitation of platelet deposition on human peripheral arterial bypass grafts using indium-111-labeled platelets: effect of dipyridamole and aspirin. Am J Cardiol 1983; 51:796-801
99. Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001; 103:961-966
100. Thompson JF, Mullee MA, Bell PRF, et al. Intraoperative heparinisation, blood loss and myocardial infarction during aortic aneurysm surgery: a joint vascular research group study. Eur J Vasc Endovasc Surg 1996; 12:86-90
101. Levy JH, Schwieger IM, Zaidan JR, et al. Evaluation of patients at risk for protamine reactions. J Thorac Cardiovasc Surg 1989; 98:200-204
102. Gupta SK, Veith FJ, Ascer E, et al. Anaphylactoid reactions to protamine: an often lethal complication in insulin-dependent diabetic patients undergoing vascular surgery. J Vasc Surg 1988; 9:342-350
103. Weiss ME, Nyhan D, Peng Z, et al. Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. N Engl J Med 1989; 320:886-892
104. Dorman BH, Elliott BM, Spinale FG, et al. Protamine reversal during peripheral vascular surgery: a prospective randomized trial. J Vasc Surg 1995; 22:248-256
105. Fearn SJ, Parry AD, Picton AJ, et al. Should heparin be reversed after carotid endarterectomy? A randomised prospective trial. Eur J Vasc Endovasc Surg 1997; 13:394-397
106. Zekert F. Klinische Anwendung von Aggregationshemmern bei arterieller Verschlusskrankheit. In: Zekert F, ed. Thrombosen, embolien und aggregationshemmer in der chirurgie. Stuttgart, Germany: Schattauer, 1977; 68-72
107. Jackson MR, Clagett GP. Antithrombotic therapy in peripheral arterial occlusive disease. Chest 2001; 119(suppl):283S-299S
108. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994; 308:159-168
109. Tangelder MJD, Algra A, Lawson JA, et al. Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery. J Vasc Surg 1999; 30:701-709
110. McCollum C, Alexander C, Kenchington G, et al. Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial. J Vasc Surg 1991; 13:150-162
111. Donaldson DR, Salter MC, Rester RC, et al. The influence of platelet inhibition on the patency of femoro-popliteal dacron bypass grafts. J Vasc Surg 1985; 19:224-230
112. Green RM, Roedersheimer LR, DeWeese JA. Effects of aspirin and dipyridamole on expanded polytetrafluoroethylene graft patency. Surgery 1982; 92:1016-1026
113. Goldman MD, McCollum CN. A prospective randomized study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoro-popliteal grafts. J Vasc Surg 1984; 18:217-221
114. Kohler TR, Kaufman JL, Kacoyanis GP, et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery 1984; 96:462-466
115. Clyne CA, Archer TJ, Atuhaire LK, et al. Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. Br J Surg 1987; 74:246-248
116. Watson HR SA, Belcher G. Graft material and results of platelet inhibitor trials in peripheral arterial reconstructions: reappraisal of results from a meta-analysis. Br J Clin Pharmacol 2000; 49:479-483
117. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomized trial. Lancet 2000; 355:346-351
118. Becquemin JP. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. N Engl J Med 1997; 337:1726-1731
119. Brown BG, Cukingnan RA, DeRouen T, et al. Improved graft patency in patients treated with platelet-inhibiting therapy after coronary bypass surgery. Circulation 1985; 72:138-146
120. Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. Circulation 1991; 83:1526-1533
121. Goldman S, Copeland J, Moritz T, et al. Starting aspirin therapy after operation. Circulation 1991; 84:520-526
122. Sethi GK, Copeland JG, Goldman S, et al. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 1990; 15:15-20
123. Kretschmer G, Herbst F, Prager M, et al. A decade of oral anticoagulant treatment to maintain antologous vein grafts for femoropopliteal atherosclerosis. Arch Surg 1992; 127:1112-1115
124. Arfvidsson B, Lundgren F, Drott C, et al. Influence on coumarin treatment on patency and limb salvage after peripheral arterial reconstructive surgery. Am J Surg 1990; 159:556-560
125. Schneider E, Brunner U, Bollinger A. Medikamentöse Rezidivprophilaxe nach fermoro-poplitealer Arterienrekon-struktion. Angiology 1979; 2:73-77
126. Sarac TP, Huber TS, Back MR, et al. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J Vasc Surg 1998; 28:446-457
127. Johnson WC, Williford WO. Benefits, morbidity and mortality associated with long-term administration of oral anticoagulants to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg 2002; 35:413-421
128. Tangelder MJD, Algra A, Lawson JA, et al. Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. J Vasc Surg 2001; 33:522-527
129. Edmondson RA, Cohen AT, Das SK, et al. Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet 1994; 344:914-918
130. Stratton JR, Zierler E, Kazmers A. Platelet deposition at carotid endarterectomy sites in humans. Stroke 1987; 18:722-727
131. Findlay JM, Lougheed WM, Gentili F, et al. Effect of perioperative platelet inhibition on postcarorid endarterectomy mural thrombus formation. J Neurosurg 1985; 63:693-698
132. Fields WS, Lemak NA, Frankowski RF, et al. Controlled trial of aspirin in cerebral ischemia: Part II. Surgical group. Stroke 1978; 9:309-319
133. Boysen G, Sorensen PS, Juhler M, et al. Danish very-low-dose aspirin after carotid endarterectomy trial. Stroke 1988; 19:1211-1215
134. Lindblad B, Persson NH, Takolander R, et al. Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A double-blind, placebo-controlled randomized trial. Stroke 1993; 24:1125-1128
135. Taylor DW, Barnett HJM, Haynes RB, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomized controlled trial. Lancet 1999; 353:2179-2184
136. Treiman RL, Cossman DV, Foran RF, et al. The influence of neutralizing heparin after carotid endarterectomy on postoperative stroke and wound hematoma. J Vasc Surg 1990; 12:440-446
137. Kunkel JM, Gomez ER, Spebar MJ, et al. Wound hematomas after carotid endarterectomy. Am J Surg 1984; 148:844-847
138. Krupski WC, Weiss DG, Rapp JH, et al. Adverse effects of aspirin in the treatment of asymptomatic carotid artery stenosis. J Vasc Surg 1992; 16:588-600
139. Hobson RW, Krupski WC, Weiss DG, et al. Influence of aspirin in the management of asymptomatic carotid artery stenosis. J Vasc Surg 1993; 17:257-265
140. Côté R, Battista RN, Abrahamowicz M, et al. Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. Ann Intern Med 1995; 123:649-655
141. Clagett GP. When should I reoperate for recurrent carotid stenosis? In: Naylor AR, Mackey WC, eds. Carotid artery surgery: a problem based approach. London, UK: WB Saunders, 2002; 375-382
142. Zierler RE, Bandyk DF, Thiele BL, et al. Carotid artery stenosis following endarterectomy. Arch Surg 1982; 117:1408-1415
143. Clagett GP, Rich NM, McDonald PT, et al. Etiologic factors for recurrent carotid artery stenosis. Surgery 1983; 93:313-318
144. Harker LA, Bernstein EF, Dilley RB, et al. Failure of aspirin plus dipyridamole to prevent restenosis after carotid endarterectomy. Ann Intern Med 1992; 116:731-736
145. TASC Working Group. Management of peripheral arterial disease (PAD): trails-Atlantic inter-societal consensus (TASC). J Vasc Surg 2000; 31:S1-S296
146. Cejna M, Thurnher S, Illiasch H, et al. PTA verus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol 2001; 12:23-31
147. Duda SH, Pusich B, Richter G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation 2002; 106:1505-1509
148. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346:177.3-1780
149. Heiss HW, Just H, Middleton D, et al. Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA. Angiology 1990; 41:263-269
150. Study Group on Pharmacological Treatment after PTA. Platelet inhibition with ASA/dipyridamole after percutaneous balloon angioplasty in patients with symptomatic lower limb arterial disease: a prospective double-blind trial. Eur J Vasc Surg 1994; 8:83-88
151. Schneider E, Mahler F, Do DD, et al. Zur rezidivprophylaxe nach perkutaner transluminaler Angioplastie (PTA): Antikoagulation versus Ticlopidin. Vasa 1987; 16(suppl 20).355-356
152. Pilger E, Lammer J, Bertuch H, et al. Nd: Yag laser with sapphire tip combined with balloon angioplasty in peripheral arterial occlusions: long-term results. Circulation 1991; 83:141-147
153. Do DD, Mahler F. Low-dose aspirin combined with dipyridamole versus anticoagulants after femoropopliteal percutaneous transluminal angioplasty. Radiology 1994; 193:567-571
154. Leon M, Baim D, Popma J, et al. A randomized trial comparing three drug regimens to prevent thrombosis following elective coronary stenting. N Engl J Med 1998; 339:1665-1671